News Moderna agrees $950m settlement of mRNA jab litigation Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.
News Moderna closes on EU approval for combined flu/COVID jab Moderna's combined vaccine for both flu and COVID-19 has been recommended for approval in the EU, after being knocked back in the US.
News Bayer's Monsanto sues mRNA COVID-19 vaccine makers Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.
News Investor seeks sale of Novavax after poor COVID jab sales Investor Shah Capital has called on Novavax's board to put the company up for sale, citing a "litany of missteps" at the vaccine developer.
News COVID-19 vaccine support reined back by ACIP The CDC's vaccine committee reduced some support for COVID-19 vaccines, but did not go as far as some might have feared in limiting access.
News Moderna cuts staff amid operating 'uncertainty' Moderna will cut another 10% of its workforce as it tries to trim $1.5 billion off its annual costs by 2027.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.